Bicara Therapeutics, a clinical-stage biopharmaceutical company focused on bifunctional therapies for solid tumors, will announce its Q1 2026 financial results and business updates on May 11, 2026, before market open. The company will hold a conference call at 8:30 a.m. ET the same day to discuss these results. Bicara is developing ficerafusp alfa, a bifunctional antibody targeting EGFR and TGF-β, aimed at treating head and neck squamous cell carcinoma and other solid tumors. This update is important as it may provide insights into the progress of their lead drug candidate and ongoing clinical trials.
On June 15, 2026, BlackRock, Inc. and its funds reduced their total holdings in Orion Corporation to below 5% of the company's shares and voting rights. This change was disclosed under the Finnish Securities Market Act, indicating a decrease from a p...
Autonomize, a healthcare AI platform, has strengthened its leadership by appointing three industry veterans to its Advisory Board and hiring Mike Longacre as Head of Transformation. These moves aim to help healthcare organizations move beyond AI pilo...
Fairfax Financial Holdings has finalized its acquisition of Kennedy-Wilson Holdings at $10.90 per share in cash, led by a consortium including Kennedy Wilson's CEO William McMorrow and affiliates of Fairfax. The Kennedy Wilson management team retains...
Aya Gold & Silver Inc., a Canadian precious metals mining company operating in Morocco, will be added to the VanEck Gold Miners ETF (GDX) effective June 19, 2026. This inclusion marks a significant milestone reflecting the company's growth in product...
Nephros, Inc. emphasizes its ultrafiltration technology's ability to capture microplastics and nanoplastics in water, following the U.S. EPA's April 2026 decision to list microplastics as a priority contaminant under the Safe Drinking Water Act. The ...
